Walking and Thinking - Brain Activity During Complex Walking in People With Multiple Sclerosis
NCT05787704, Completed, Karolinska Institutet
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Walking and Thinking - Brain Activity During Complex Walking in People With Multiple Sclerosis | ClinicalTrials.gov |
| NCT number | NCT05787704 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 41 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Karolinska Institutet | ClinicalTrials.gov |
| Conditions | Multiple Sclerosis, Gait Disorders, Neurologic, Neuro-Degenerative Disease, Aging | ClinicalTrials.gov |
| Interventions | No intervention | ClinicalTrials.gov |
| First posted | 2023-03-28 | ClinicalTrials.gov |
| Last updated | 2024-10-24 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Functional near infrared spectrometry (fNIRS) | During the test session during all three conditions | The measurement of changes in concentration of HbO and HHb in the prefrontal cortex will be assessed using a NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) device. | ClinicalTrials.gov |
| Primary | Gait performance during all conditions | During the test session during all three conditions | Gait variables such as stride time and/or velocity will be analyzed with the APDM mobility system. | ClinicalTrials.gov |
| Primary | Dual-task performance-reaction time | During the test session during complex walking condition 1 and 3 | Cognitive performance of the dual task will be assessed as errors in the response to the Auditory stroop task. | ClinicalTrials.gov |
| Secondary | Cognitive function- composite score | During the test session, takes about 50 minutes | The cognitive test battery comprised the following tests: The Color-Word Interference Test (CWIT), Verbal Fluency, Trail Making Test (TMT) and Ray Auditory Verbal Learning Test (RAVLT) and Symbol Digit Modalities Test (SDMT). Cognitive function will be assessed as a composite measure of these test together. | ClinicalTrials.gov |
| Secondary | Cognitive function - verbal fluency | During the test session, takes about 12 minutes | Verbal function, initiation \& task-set switching with the Verbal Fluency test from D-KEFS (Delis-Kaplan Executive Function System). | ClinicalTrials.gov |
| Secondary | Cognitive function - Attention and psychomotor processing speed | During the test session, takes about 3 minutes | Attention and psychomotor processing speed will be assessed with the Trail Making Test (TMT) from D-KEFS (Delis-Kaplan Executive Function System). | ClinicalTrials.gov |
| Secondary | Cognitive function - Episodic memory | During the test session, takes about 30 minutes | Episodic memory will be assessed with the Ray Auditory Verbal Learning Test (RAVLT). | ClinicalTrials.gov |
| Secondary | Cognitive function - Cognitive processing speed | During the test session, takes about 3 minutes | Cognitive processing speed will be assessed with the Symbol Digit Modalities Test (SDMT) | ClinicalTrials.gov |
| Secondary | Cognitive function - Inhibition & task-set switching | During the test session, takes about 5 minutes | Inhibition \& task-set switching with the The Color-Word Interference Test (CWIT) from D-KEFS (Delis-Kaplan Executive Function System). | ClinicalTrials.gov |
| Secondary | Self-reported level of physical activity | Will be answered before the test session in the patients home or during the test session | Assessed with the Frändin-Grimby Scale (score 1-6, higher score=better) | ClinicalTrials.gov |
| Secondary | Physical activity level and intensity | For one week after the test session | Assessed with accelerometers (Actigraph GT3X+) | ClinicalTrials.gov |
| Secondary | Overall MS-disability | During the test session | Assessed with the Expanded Disability Status Scale (EDSS). Higher scores=worse/more severe disability | ClinicalTrials.gov |
| Secondary | Balance performance | During the test session | Assessed with the Mini-BESTest (Balance Evaluation Systems test), 0-28p. | ClinicalTrials.gov |
| Secondary | Anxiety and depression | Will be answered before the test session in the patients home or during the test session | Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better | ClinicalTrials.gov |
| Secondary | Walking ability | Will be answered before the test session in the patients home or at the test session | Self-assessed walking ability with the WALK-12G. | ClinicalTrials.gov |
| Secondary | Dual-task performance -errors | During the test session during dual task conditions | Cognitive performance of the dual task will be assessed as the reaction time to respond during Auditory stroop | ClinicalTrials.gov |
| Secondary | Disability | Will be answered before the test session in the patients home or during the test session | WHO Disability Assessment Schedule (WHODAS) version 2.0, 12 self-assessed questions (12 to 60) more points=worse | ClinicalTrials.gov |
| Secondary | Impact of Fatigue | Will be answered before the test session in the patients home or during the test session | Self-assessed impact of fatigue on physical, cognitive, and psychosocial functioning, with the Modified Fatigue Impact Scale (MFIS). 21 items, scored from 0 to 4. Higher scores indicate a larger impact of fatigue. | ClinicalTrials.gov |
| Secondary | Impact of MS on health | Will be answered before the test session in the patients home or during the test session | Self-assessed physical and psychological impact of MS on health. 29 items, rated from 1 to 5. Higher score indicates perceived worse physical or psychological impacts of MS, respectively, on health. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)